197P - The risk of uterine cervical cancer in inflammatory bowel disease: An updated systematic review and meta-analysis

Background

There is few information on association between incidence of uterine cervical cancer in patients with inflammatory bowel disease (IBD). The aim of this systematic review and meta-analysis was to assess risk of uterine cervical cancer in patients with IBD.

Methods

MEDLINE, Embase, The Cochrane Library, Scopus, and Web of Science, ClinicalTrials.gov, other sources of grey literature, and conference proceedings were used to search for studies published before 21 January 2022. The Newcastle-Ottawa-Scale was used to evaluate the quality of each included studies.

Results

From multiple search databases and trials registries, 1652 records were identified after duplicates removed in the initial search. After screening, 24 and 15 studies were included for qualitative and quantitative synthesis, respectively. The pooled relative risk (RR) of risk of uterine cervical cancer in IBD patients was 1.38 (95% CI, 1.10-1.74; I²=55.0%). The pooled RR of uterine cervical cancer in CD and UC patients were 1.18 (95% CI, 0.97-1.42; I²=11.6%) and 1.50 (95% CI, 1.01-2.21; I²=72.5%), respectively. The pooled RR of uterine cervical cancer in pre-biologic era (before 1998) and biologic era (after 1998) were 1.37 (95% CI, 0.84-2.24; I²=0.0%) and 1.79 (95% CI, 1.04-3.06; I²=75.3%), respectively).

Conclusions

The risk of uterine cervical cancer was not significantly increased in CD, but significantly increased in UC. Since the risk of uterine cervical cancer in biologic era was significantly increased, while insignificant in pre-biologic era, further investigation on the impact of biologics on uterine cervical cancer in patients with IBD is needed.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

The Korea Medical Device Development Fund grant.

Disclosure

All authors have declared no conflicts of interest.